

European Journal of Pharmaceutics and Biopharmaceutics

www.elsevier.com/locate/ejpb

Aims and Scope

The *European Journal of Pharmaceutics and Biopharmaceutics* provides a medium for publication of novel and innovative research from the areas of Pharmaceutical Technology, Pharmaceutical Biotechnology and Biopharmaceutics.

Topics covered include: • Drug and pro-drug design, drug stability and drug development • Development, formulation and manufacturing of pharmaceuticals and biopharmaceuticals • Physical pharmacy, drug delivery systems, controlled release systems and drug targeting • Biopharmaceutics • Pharmaceutical analysis and pharmaceutical packaging • Quality control, GMP and regulatory aspects • Medical devices.

The following types of papers are considered by the Editors: Research Papers, Review Articles and Notes.

The Rules of 3

The Editors and Editorial board have developed the “**Rules of 3**”. Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work:

1. The paper must report on recent advances in pharmaceutical technology, biopharmaceutics and pharmaceutical biotechnology of major importance.
2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
3. The study described in the manuscript must represent a novel approach.

The rules are also used as guidelines for the peer review of manuscripts and are detailed on the journal homepage www.elsevier.com/locate/ejpb

Editor-in-Chief

Prof. Robert Gurny, School of Pharmaceutical Sciences, University of Geneva, 30, quai E.-Ansermet, CH-1211 Geneva 4, Switzerland

Editors

Prof. Gerrit Borchard, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

Prof. Achim Göpferich, Institute of Pharmacy, Pharmaceutical Technology, University of Regensburg, Regensburg, Germany

Prof. Geoffrey Lee, Institute for Pharmaceutical Technology, University of Erlangen-Nürnberg, Erlangen, Germany

Prof. Claus-Michael Lehr, University of Saarland, Department of Biopharmaceutics and Pharmaceutical Technology, Saarbrücken, Germany

Prof. Jean-Christophe Leroux, Galénische Pharmazie ETH, Zurich, Switzerland

Prof. Karsten Mäder, Institute of Pharmacy, Pharmaceutical Technology, Martin Luther University, Halle/Saale, Germany

Prof. James W. McGinity, College of Pharmacy, Drug Dynamics Institute, The University of Texas at Austin, Austin, TX, USA

Associate Editor

Dr. Michael Möller, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

Editorial Advisory Board

E. Allémann, University of Geneva, Switzerland

J.M. Anderson, Case Western Reserve University, Cleveland, OH, USA

S. Benita, Hebrew University of Jerusalem, Israel

J.-P. Benoit, University of Angers, France

A. Bernkop-Schnürch, University of Innsbruck, Austria

M.J. Blanco-Prieto, University of Navarra, Pamplona, Spain

R. Bodmeier, Freie University of Berlin, Germany

J. Breitenbachm, Abbott GmbH & Co. KG, Ludwigshafen, Germany

P. Breton, Wavre, Belgium

H. Bunjes, Technical University of Braunschweig, Germany

U. Conte, University of Pavia, Italy

P. Couvreur, University of Paris Sud, France

R. Daniels, University of Tübingen, Germany

F. Delie-Salmon, University of Geneva, Switzerland

J.M. Devoisselle, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier, France

E. Doelker, University of Geneva, Switzerland

J. Dressman, J.W. Goethe University, Frankfurt, Germany

P. Esposito, Esteve, Martorelles, Spain

B. Gander, ETH Zürich, Switzerland

W.R. Gombotz, Omeros Corp., Seattle, WA, USA

M. Gonzalez, P'Kinetics International, Pembroke Pines, FL, USA

R.H. Guy, University of Bath, UK

J. Hadgraft, University of London, UK

J.A. Hubbell, EPFL, Lausanne, Switzerland

H.E. Junginger, Marburg, Germany

Y.N. Kalia, University of Geneva, Switzerland

T. Kissel, Philipps University, Marburg, Germany

P. Kleinebudde, H.-Heine University, Düsseldorf, Germany

J. Knäblein, Schering AG, Berlin, Germany

J. Kopecek, University of Utah, Salt Lake City, UT, USA

J. Kreuter, J.W. Goethe University, Frankfurt, Germany

V.H.L. Lee, The Chinese University of Hong Kong, Shatin, Hong Kong

H. Lindner, Bayer Schering Pharma AG, Berlin, Germany

H.L. Luessen, Tytonis BV, Alkmaar, The Netherlands

E. Mathiowitz, Brown University, Providence, RI, USA

F.W.H.M. Merkus, Leiden/Amsterdam Center for Drug Research, The Netherlands

R.H. Müller, Freie University of Berlin, Germany

C. Müller-Goymann, University of Braunschweig, Germany

T. Nagai, The Nagai Foundation, Tokyo, Japan

R.H.H. Neubert, Martin Luther University, Halle, Germany

A.F. Öner, Hacettepe University, Ankara, Turkey

G.M. Pauletti, University of Cincinnati, OH, USA

N.A. Peppas, University of Texas, Austin, TX, USA

V. Préat, Université Catholique de Louvain, Belgium

S. Rudaz, University of Geneva, Switzerland

C. Rudolph, Ludwig Maximilians University, Munich, Germany

L. Scapozza, University of Geneva, Switzerland

R. Schubert, Albert Ludwigs University, Freiburg, Germany

J. Siepmann, University of Lille, France

K.J. Tojo, Kyushu Institute of Technology, Izuka, Fukuoka, Japan

V. Torchilin, Northeastern University, Boston, MA, USA

C. Valenta, University of Vienna, Austria

J.L. Veuthey, University of Geneva, Switzerland

W. Weitschies, University of Greifswald, Germany

C.G. Wilson, University of Strathclyde, Glasgow, UK

G. Winter, Ludwig Maximilian University, Munich, Germany

A. Zimmer, University of Graz, Austria